- Conditions
- Venous Thromboembolism
- Interventions
- dabigatran etexilate 150 mg twice daily (BID), matching placebo twice daily (BID)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Laguna Hills, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Thromboembolism
- Interventions
- dabigatran etexilate 150 mg, warfarin (INR 2-3)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 19 more
- Conditions
- Thromboembolism
- Interventions
- Warfarin, Dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,589 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more
- Conditions
- Symptomatic Venous Thromboembolism (VTE)
- Interventions
- REGN7508, Acetylsalicylic Acid (ASA), Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 38
- States / cities
- La Mesa, California • Rancho Mirage, California • Riverside, California + 30 more
- Conditions
- Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism
- Interventions
- BAY 59-7939, ASA
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 24
- States / cities
- Beverly Hills, California • La Jolla, California • Ventura, California + 19 more
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
- Interventions
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 82
- States / cities
- Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more